Compare LUCD & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LUCD | EARN |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.4M | 169.8M |
| IPO Year | 2021 | 2012 |
| Metric | LUCD | EARN |
|---|---|---|
| Price | $1.00 | $4.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $4.13 | ★ $5.38 |
| AVG Volume (30 Days) | ★ 1.7M | 382.8K |
| Earning Date | 05-13-2026 | 06-16-2026 |
| Dividend Yield | N/A | ★ 20.51% |
| EPS Growth | ★ 16.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,346,000.00 | N/A |
| Revenue This Year | $115.58 | $7.69 |
| Revenue Next Year | $130.54 | $19.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 79.00 | N/A |
| 52 Week Low | $0.90 | $4.27 |
| 52 Week High | $1.63 | $6.08 |
| Indicator | LUCD | EARN |
|---|---|---|
| Relative Strength Index (RSI) | 47.21 | 43.74 |
| Support Level | $1.01 | $4.31 |
| Resistance Level | $1.11 | $4.78 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 39.39 | 34.72 |
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Ellington Credit Co The Fund is focused on acquiring and actively managing a portfolio of corporate CLOs, mainly mezzanine debt and equity tranches, which are typically collateralized by portfolios consisting mainly of below-investment-grade senior secured loans with a large number of discrete underlying borrowers across various industry sectors. Additionally, the Fund may also invest in CLO loan accumulation facilities, which are entities that acquire corporate loans and other similar corporate credit-related assets in anticipation of ultimately collateralizing a CLO transaction. The company's primary investment objectives are to generate attractive current income and risk-adjusted total returns for shareholders.